Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Pfizer pledges $100M to new Antimicrobial Resistance Action Fund » 15:23
07/09/20
07/09
15:23
07/09/20
15:23
PFE

Pfizer

$33.57 /

-0.19 (-0.56%)

, AMGN

Amgen

$252.34 /

+0.74 (+0.29%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, LLY

Eli Lilly

$166.59 /

-2.52 (-1.49%)

, GSK

GlaxoSmithKline

$40.37 /

-0.35 (-0.86%)

, MRK

Merck

$76.99 /

-0.88 (-1.13%)

, MKGAY

Merck KGaA

$0.00 /

+ (+0.00%)

, TEVA

Teva

$11.60 /

+0.21 (+1.84%)

, TAK

Takeda Pharmaceutical

$17.36 /

-0.135 (-0.77%)

, NVO

Novo Nordisk

$65.63 /

-0.23 (-0.35%)

, JNJ

Johnson & Johnson

$143.03 /

-0.21 (-0.15%)

, NVS

Novartis

$87.53 /

-0.585 (-0.66%)

Pfizer (PFE) announced…

Pfizer (PFE) announced earlier it has pledged $100M to the new Antimicrobial Resistance, or "AMR," Action Fund, which launched today, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections. "The AMR Action Fund is a ground-breaking collaboration among more than 20 biopharmaceutical companies that aims to bring 2-4 new antibiotics to patients by 2030 through collaboration between pharmaceutical companies, philanthropies, development banks, and multilateral organizations to re-invigorate and accelerate antibiotic development," the company stated. "As the COVID-19 pandemic has shown, we must invest in the development of medicines now so that we are prepared to help prevent the next public health crisis," added Pfizer Chairman and CEO Albert Bourla. Other investors in the AMR Action Fund include Amgen (AMGN), Bayer (BAYRY), Roche (RHHBY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Merck (MRK), Merck KGaA (MKGAY), Teva (TEVA), Takeda Pharmaceutical (TAK), Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Novartis (NVS). Reference Link

ShowHide Related Items >><<
TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
AMGN Amgen
$252.34 /

+0.74 (+0.29%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

10:13 Today Morgan Stanley
Eli Lilly won't publish Phase 1 COVID antibody data, says Morgan Stanley
06/29/20 Mizuho
Eli Lilly price target raised to $164 from $155 at Mizuho
06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
MRK Merck
$76.99 /

-0.88 (-1.13%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

05/15/20 Nord/LB
Merck KGaA downgraded to Hold from Buy at Nord/LB
03/06/20 UBS
UBS backs Neutral on Merck KGaA after Q4 results
12/02/19 Goldman Sachs
Merck KGaA reinstated with a Sell at Goldman Sachs
10/04/19 Loop Capital
Entegris price target raised to $51 from $47 at Loop Capital
TEVA Teva
$11.60 /

+0.21 (+1.84%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$87.53 /

-0.585 (-0.66%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
TEVA Teva
$11.60 /

+0.21 (+1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

Conference/Events
Oxford Global Marketing to hold a virtual event » 04:55
07/09/20
07/09
04:55
07/09/20
04:55
ABBV

AbbVie

$99.28 /

-0.06 (-0.06%)

, AZN

AstraZeneca

$54.19 /

+0.7 (+1.31%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$59.58 /

-0.72 (-1.19%)

, GSK

GlaxoSmithKline

$40.72 /

+0.34 (+0.84%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

, JAZZ

Jazz Pharmaceuticals

$107.54 /

-1.18 (-1.09%)

, JNJ

Johnson & Johnson

$143.24 /

+0.43 (+0.30%)

, NVS

Novartis

$88.12 /

+0.345 (+0.39%)

, PFE

Pfizer

$33.76 /

-0.27 (-0.79%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RTRX

Retrophin

$20.86 /

-0.04 (-0.19%)

, SNY

Sanofi

$51.54 /

+0.14 (+0.27%)

, TAK

Takeda Pharmaceutical

$17.49 /

+0.01 (+0.06%)

, TEVA

Teva

$11.39 /

+0.17 (+1.52%)

Formulation &…

Formulation & Delivery Series Biomanufacturing Virtual Congress will be held on July 8-9. Webcast Link

ShowHide Related Items >><<
TEVA Teva
$11.39 /

+0.17 (+1.52%)

TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RTRX Retrophin
$20.86 /

-0.04 (-0.19%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

07/07/20 SunTrust
Evolus price target lowered to $6 from $12 at SunTrust
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
06/29/20 Mizuho
AbbVie price target raised to $110 from $101 at Mizuho
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
IPSEY Ipsen
$0.00 /

+ (+0.00%)

06/08/20 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
06/01/20 Barclays
Ipsen price target raised to EUR 72 from EUR 62 at Barclays
06/01/20 BofA
Ipsen upgraded to Buy from Neutral at BofA
05/18/20 JPMorgan
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan
JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

06/23/20 Barclays
Jazz Pharmaceuticals price target raised to $195 from $183 at Barclays
06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$88.12 /

+0.345 (+0.39%)

07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.76 /

-0.27 (-0.79%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
RTRX Retrophin
$20.86 /

-0.04 (-0.19%)

06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
08/23/19 BMO Capital
Retrophin price target lowered to $33 from $38 at BMO Capital
SNY Sanofi
$51.54 /

+0.14 (+0.27%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TEVA Teva
$11.39 /

+0.17 (+1.52%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TEVA Teva
$11.39 /

+0.17 (+1.52%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RTRX Retrophin
$20.86 /

-0.04 (-0.19%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

  • 09
    Jun
TEVA Teva
$11.39 /

+0.17 (+1.52%)

TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

TEVA Teva
$11.39 /

+0.17 (+1.52%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

TEVA Teva
$11.39 /

+0.17 (+1.52%)

TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

Yesterday
Conference/Events
Oxford Global Marketing to hold a virtual event » 09:24
07/08/20
07/08
09:24
07/08/20
09:24
ABBV

AbbVie

$99.34 /

+0.31 (+0.31%)

, AZN

AstraZeneca

$53.49 /

-0.61 (-1.13%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$60.30 /

+0.09 (+0.15%)

, GSK

GlaxoSmithKline

$40.38 /

-0.625 (-1.52%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

, JAZZ

Jazz Pharmaceuticals

$108.72 /

-2.48 (-2.23%)

, JNJ

Johnson & Johnson

$142.81 /

-0.18 (-0.13%)

, NVS

Novartis

$87.77 /

-0.65 (-0.74%)

, PFE

Pfizer

$34.03 /

-0.48 (-1.39%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RTRX

Retrophin

$20.90 /

+0.34 (+1.65%)

, SNY

Sanofi

$51.40 /

-0.78 (-1.49%)

, TAK

Takeda Pharmaceutical

$17.48 /

-0.18 (-1.02%)

, TEVA

Teva

$11.22 /

-0.31 (-2.69%)

Formulation &…

Formulation & Delivery Series Biomanufacturing Virtual Congress will be held on July 8-9. Webcast Link

ShowHide Related Items >><<
TEVA Teva
$11.22 /

-0.31 (-2.69%)

TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RTRX Retrophin
$20.90 /

+0.34 (+1.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

07/07/20 SunTrust
Evolus price target lowered to $6 from $12 at SunTrust
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
06/29/20 Mizuho
AbbVie price target raised to $110 from $101 at Mizuho
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
IPSEY Ipsen
$0.00 /

+ (+0.00%)

06/08/20 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
06/01/20 Barclays
Ipsen price target raised to EUR 72 from EUR 62 at Barclays
06/01/20 BofA
Ipsen upgraded to Buy from Neutral at BofA
05/18/20 JPMorgan
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan
JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

06/23/20 Barclays
Jazz Pharmaceuticals price target raised to $195 from $183 at Barclays
06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$87.77 /

-0.65 (-0.74%)

07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$34.03 /

-0.48 (-1.39%)

07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
RTRX Retrophin
$20.90 /

+0.34 (+1.65%)

06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
08/23/19 BMO Capital
Retrophin price target lowered to $33 from $38 at BMO Capital
SNY Sanofi
$51.40 /

-0.78 (-1.49%)

07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
06/24/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TEVA Teva
$11.22 /

-0.31 (-2.69%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TEVA Teva
$11.22 /

-0.31 (-2.69%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RTRX Retrophin
$20.90 /

+0.34 (+1.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

  • 09
    Jun
TEVA Teva
$11.22 /

-0.31 (-2.69%)

TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

TEVA Teva
$11.22 /

-0.31 (-2.69%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

TEVA Teva
$11.22 /

-0.31 (-2.69%)

TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

Over a week ago
Recommendations
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo » 07:37
07/02/20
07/02
07:37
07/02/20
07:37
EBS

Emergent BioSolutions

$81.89 /

+2.9 (+3.67%)

, TEVA

Teva

$11.52 /

-0.8 (-6.49%)

Wells Fargo analyst…

Wells Fargo analyst Jacobs Hughes raised the firm's price target on Emergent BioSolutions (EBS) to $93 from $85 and keeps an Overweight rating on the shares. The analyst notes that on June 5, Emergent received a negative ruling in the Teva (TEVA) Narcan Nasal Spray patent case, invalidating 4 EBS patents. EBS is expected to file an appeal, with a decision expected in the second half of 2021. Judge Martinotti's redacted judgement was recently released, and Hughes' patent consultant reviewed the opinion, saying he believes it's highly unlikely an appeal will be successful. The analyst's model now assumes generics enter in the second half of 2021 and expects Narcan revenue to decline materially over the ensuing several years. That said, after reviewing his model and several recent CDMO wins, Hughes sees equity upside potential from current levels based on his SOTP analysis where he continues to believe the CDMO business is undervalued based on recent wins and public comps.

ShowHide Related Items >><<
TEVA Teva
$11.52 /

-0.8 (-6.49%)

EBS Emergent BioSolutions
$81.89 /

+2.9 (+3.67%)

EBS Emergent BioSolutions
$81.89 /

+2.9 (+3.67%)

06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
06/02/20 Guggenheim
Emergent BioSolutions price target raised to $101 from $81 at Guggenheim
02/25/20 Wells Fargo
Emergent BioSolutions price target raised to $75 from $66 at Wells Fargo
TEVA Teva
$11.52 /

-0.8 (-6.49%)

06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/01/20
Fly Intel: Top five analyst upgrades
TEVA Teva
$11.52 /

-0.8 (-6.49%)

EBS Emergent BioSolutions
$81.89 /

+2.9 (+3.67%)

TEVA Teva
$11.52 /

-0.8 (-6.49%)

TEVA Teva
$11.52 /

-0.8 (-6.49%)

EBS Emergent BioSolutions
$81.89 /

+2.9 (+3.67%)

TEVA Teva
$11.52 /

-0.8 (-6.49%)

Recommendations
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair » 11:59
06/26/20
06/26
11:59
06/26/20
11:59
PFNX

Pfenex

$7.81 /

-0.77 (-8.97%)

, TEVA

Teva

$12.40 /

-0.33 (-2.59%)

Europe's Committee…

Europe's Committee for Medicinal Products for Human Use today adopted a positive opinion recommending the approval of Livogiva by Pfenex's (PFNX) partners Alvogen/Theramex, William Blair analyst Andy Hsieh tells investors in a research note. However, there is some confusion regarding the sponsor due to inaccurate information distributed by a provider of equity market intelligence, the analyst adds. However, Hsieh "can unequivocally state" that Livogiva is from Pfenex's collaborator Alvogen/Theramex and not Teva's (TEVA) synthetic teriparatide. He views the recommendation as a "material de-risking event" for the European market. Furthermore, the European opportunity is one of the important geographies as the PF708 franchise expands globally, says Hsieh. The analyst notes that Pfenex is eligible to receive a gross profit split of up to 60%, dependent on product sales. The stock in midday trading is down 8% to $7.89.

ShowHide Related Items >><<
TEVA Teva
$12.40 /

-0.33 (-2.59%)

PFNX Pfenex
$7.81 /

-0.77 (-8.97%)

PFNX Pfenex
$7.81 /

-0.77 (-8.97%)

06/15/20 Oppenheimer
Pfenex price target raised to $15 from $10 at Oppenheimer
06/01/20 Oppenheimer
Pfenex assumed with an Outperform at Oppenheimer
04/23/20
Fly Intel: Top five analyst initiations
04/22/20 Oppenheimer
Pfenex initiated with an Outperform at Oppenheimer
TEVA Teva
$12.40 /

-0.33 (-2.59%)

06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
06/01/20
Fly Intel: Top five analyst upgrades
06/01/20 SunTrust
Teva upgraded to Buy from Hold at SunTrust
TEVA Teva
$12.40 /

-0.33 (-2.59%)

PFNX Pfenex
$7.81 /

-0.77 (-8.97%)

TEVA Teva
$12.40 /

-0.33 (-2.59%)

TEVA Teva
$12.40 /

-0.33 (-2.59%)

TEVA Teva
$12.40 /

-0.33 (-2.59%)

Options
Teva call volume above normal and directionally bullish » 14:45
06/25/20
06/25
14:45
06/25/20
14:45
TEVA

Teva

$12.57 /

-0.075 (-0.59%)

Bullish option flow…

Bullish option flow detected in Teva with 15,887 calls trading, 1.3x expected, and implied vol increasing over 1 point to 54.96%. Aug-20 15 calls and 6/26 weekly 13 calls are the most active options, with total volume in those strikes near 11,200 contracts. The Put/Call Ratio is 0.12. Earnings are expected on August 5th.

ShowHide Related Items >><<
TEVA Teva
$12.57 /

-0.075 (-0.59%)

TEVA Teva
$12.57 /

-0.075 (-0.59%)

06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
06/01/20
Fly Intel: Top five analyst upgrades
06/01/20 SunTrust
Teva upgraded to Buy from Hold at SunTrust
TEVA Teva
$12.57 /

-0.075 (-0.59%)

TEVA Teva
$12.57 /

-0.075 (-0.59%)

TEVA Teva
$12.57 /

-0.075 (-0.59%)

TEVA Teva
$12.57 /

-0.075 (-0.59%)

Hot Stocks
Teva announces new Ajovy data from FOCUS study » 08:23
06/18/20
06/18
08:23
06/18/20
08:23
TEVA

Teva

$12.04 /

-0.015 (-0.12%)

Teva announced new data…

Teva announced new data examining quality of life, health status, depressive symptoms, work productivity and activity impairment of patients treated with Ajovy during the 12-week open-label extension of the Phase IIIb FOCUS study. An additional analysis of pooled results from three Ajovy Phase III trials examined headache- and migraine-related disability based on guidelines set forth by the American Headache Society. The data were presented at the AHS Virtual Annual Scientific Meeting. The following results were observed in quality of life, health status, depressive symptoms, and work productivity based on scores from validated patient-reported questionnaires, including Migraine-Specific Quality of Life, or MSQoL, 5-level EuroQol-5 Dimension, or EQ-5D-5L, Patient Global Impression of Change, or PGIC, 9-item Patient Health Questionnaire, or PHQ-9 and Work Productivity and Activity Impairment, or WPAI, questionnaire. MSQoL quality-of-life domain scores and the EQ-5D-5L health status score at the end of the double-blind period and through the end of the open-label extension. The proportion of patients who experienced a response on the PGIC increased from 58% to 64% at the end of the double-blind period to 75% to 77% at the end of the open-label extension. Depressive symptom scores were reduced by 1.6 to 2.4 points by the end of the open-label extension. Overall, 14.5% to 20% reductions from baseline were reported in overall health-related work impairment by the end of the open-label extension. Additionally, the safety and tolerability of Ajovy during this open-label extension was evaluated, with the most common adverse events, or AEs, being injection-site reactions, such as injection-site erythema. The reports of AEs leading to discontinuation were less than 1% and 3% for serious AEs. The AHS Consensus Statement provides guidelines on determining response to CGRP pathway targeted treatments for migraine. As changes in migraine frequency may not adequately assess treatment benefit in all patients, these guidelines recommended specific improvements in disability scores on the MIDAS and HIT-6 that would be considered clinically meaningful and evidence of response to treatment. The disability in patients treated with Ajovy was evaluated using pooled data from the three double-blind Phase III trials. A post-hoc analysis of the pooled Phase III study data based on guidelines set forth by the Consensus Statement noted Ajovy patients experiencing severe disability due to migraine at baseline achieved the following disability score reductions: For patients with a baseline MIDAS score of 11-20, the proportion of patients achieving a 5-point reduction from their baseline score was 71% and 70% with Ajovy and 49% with placebo. The proportion of patients with a baseline MIDAS score of greater than 20 who achieved a 0% reduction in points was 69% and 79% with AJOVY and 58% with placebo. The proportion of patients achieving a 5-point reduction from baseline in HIT-6 scores was 53% and 55% with Ajovy and 39% with placebo.

ShowHide Related Items >><<
TEVA Teva
$12.04 /

-0.015 (-0.12%)

TEVA Teva
$12.04 /

-0.015 (-0.12%)

06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
06/01/20
Fly Intel: Top five analyst upgrades
06/01/20 SunTrust
Teva upgraded to Buy from Hold at SunTrust
TEVA Teva
$12.04 /

-0.015 (-0.12%)

TEVA Teva
$12.04 /

-0.015 (-0.12%)

TEVA Teva
$12.04 /

-0.015 (-0.12%)

TEVA Teva
$12.04 /

-0.015 (-0.12%)

Recommendations
Amarin settlement with Apotex an 'incremental positive,' says Stifel » 08:28
06/17/20
06/17
08:28
06/17/20
08:28
AMRN

Amarin

$6.88 /

+0.03 (+0.44%)

, RDY

Dr. Reddy's

$53.06 /

-0.69 (-1.28%)

, TEVA

Teva

$12.05 /

+0.55 (+4.78%)

Stifel analyst Derek…

Stifel analyst Derek Archila reiterates his Hold rating on Amarin (AMRN) shares after the company settled with Apotex regarding its ANDA application for generic Vascepa. Apotex cannot sell a generic version of Vascepa until August 2029, which is the same date as Amarin's settlement with Teva (TEVA), noted Archila. While this settlement with another generic ANDA filer is an "incremental positive," Archila doesn't see this a major stock moving catalyst since Apotex is not a party in the ongoing appeal of the district court's decision invalidating Vascepa's patents, he tells investors. He expects Amarin shares to remain range-bound until closer to the hearing on the Hikma and Dr. Reddy's (RDY) case later this year, added Archila.

ShowHide Related Items >><<
TEVA Teva
$12.05 /

+0.55 (+4.78%)

RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
05/22/20 Roth Capital
Roth sees low likelihood of at-risk generic launch of Vascepa
05/22/20 Roth Capital
Amarin selloff today a buying opportunity, says Roth Capital
RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

04/21/20 Nomura Instinet
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
03/13/20 Goldman Sachs
Amarin upgraded to Buy from Neutral at Goldman Sachs
02/26/20 H.C. Wainwright
H.C. Wainwright reiterates $51 price target on Amarin shares post Q4 results
TEVA Teva
$12.05 /

+0.55 (+4.78%)

06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
06/01/20
Fly Intel: Top five analyst upgrades
06/01/20 SunTrust
Teva upgraded to Buy from Hold at SunTrust
06/01/20 SunTrust
Teva upgraded to Buy from Hold at SunTrust
TEVA Teva
$12.05 /

+0.55 (+4.78%)

RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

TEVA Teva
$12.05 /

+0.55 (+4.78%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

TEVA Teva
$12.05 /

+0.55 (+4.78%)

RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

TEVA Teva
$12.05 /

+0.55 (+4.78%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

Hot Stocks
FDA revokes emergency use authorization for hydroxychloroquine for COVID-19 » 11:55
06/15/20
06/15
11:55
06/15/20
11:55
MYL

Mylan

$15.75 /

-0.22 (-1.38%)

, TEVA

Teva

$11.23 /

-0.015 (-0.13%)

, NVS

Novartis

$84.95 /

+0.59 (+0.70%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

In an alert dated June…

In an alert dated June 15, the FDA stated: "Based on FDA's continued review of the scientific evidence available for hydroxychloroquine sulfate and chloroquine phosphate to treat COVID-19, FDA has determined that the statutory criteria for EUA as outlined in Section 564(c)(2) of the Food, Drug, and Cosmetic Act are no longer met. Specifically, FDA has determined that CQ and HCQ are unlikely to be effective in treating COVID-19 for the authorized uses in the EUA. Additionally, in light of ongoing serious cardiac adverse events and other serious side effects, the known and potential benefits of CQ and HCQ no longer outweigh the known and potential risks for the authorized use. This warrants revocation of the EUA for HCQ and CQ for the treatment of COVID-19." Mylan (MYL), Teva (TEVA), Novartis (NVS), and Bayer (BAYRY) are among companies that had announced efforts to increase hydroxychloroquine production early in the COVID-19 outbreak. Reference Link

ShowHide Related Items >><<
TEVA Teva
$11.23 /

-0.015 (-0.13%)

NVS Novartis
$84.95 /

+0.59 (+0.70%)

MYL Mylan
$15.75 /

-0.22 (-1.38%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

MYL Mylan
$15.75 /

-0.22 (-1.38%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
TEVA Teva
$11.23 /

-0.015 (-0.13%)

06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
06/01/20
Fly Intel: Top five analyst upgrades
06/01/20 SunTrust
Teva upgraded to Buy from Hold at SunTrust
06/01/20 SunTrust
Teva upgraded to Buy from Hold at SunTrust
NVS Novartis
$84.95 /

+0.59 (+0.70%)

06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
05/18/20 Jefferies
Jefferies names Beazley, Ferguson, Novartis, Rio Tinto high conviction ideas
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/08/20 Monness Crespi
Corteva downgraded to Sell from Neutral at Monness Crespi
06/04/20 BMO Capital
Dicamba ruling likely a mid-term positive for Corteva, says BMO Capital
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
04/22/20 Morgan Stanley
Bayer price target lowered to EUR 83 from EUR 86 at Morgan Stanley
TEVA Teva
$11.23 /

-0.015 (-0.13%)

NVS Novartis
$84.95 /

+0.59 (+0.70%)

MYL Mylan
$15.75 /

-0.22 (-1.38%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$11.23 /

-0.015 (-0.13%)

MYL Mylan
$15.75 /

-0.22 (-1.38%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$11.23 /

-0.015 (-0.13%)

NVS Novartis
$84.95 /

+0.59 (+0.70%)

MYL Mylan
$15.75 /

-0.22 (-1.38%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$11.23 /

-0.015 (-0.13%)

NVS Novartis
$84.95 /

+0.59 (+0.70%)

MYL Mylan
$15.75 /

-0.22 (-1.38%)

Hot Stocks
51 attorneys general file antitrust lawsuit against generic drug makers » 10:59
06/10/20
06/10
10:59
06/10/20
10:59
TARO

Taro Pharmaceutical

$66.78 /

-1.24 (-1.82%)

, TEVA

Teva

$12.32 /

-0.36 (-2.84%)

, MYL

Mylan

$17.84 /

-0.61 (-3.31%)

, PRGO

Perrigo

$55.26 /

-0.705 (-1.26%)

, NVS

Novartis

$88.16 /

-0.29 (-0.33%)

New York Attorney General…

New York Attorney General Letitia James, as part of a coalition of 51 attorneys general from around the nation, today filed an antitrust complaint in federal court alleging that individual executives and manufacturers of dermatological, generic drugs engaged in a "widespread conspiracy to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade for generic drugs sold across the United States." The complaint alleges "broad, coordinated, and systematic antitrust violations, price-fixing, market allocating, and the rigging of bids for more than 80 different topical, generic drugs." The complaint names as defendants 26 generic, dermatological drug manufacturers and 10 individual executives at these companies. From at least 2007 through 2014, three manufacturers - Taro (TARO), Perrigo (PRGO), and Sandoz (NVS) - sold approximately two-thirds of all the generic topical products dispensed in the United States, James says in a statement. "In an effort to manipulate the market and consume a larger share of the market than would otherwise be allowed, these companies repeatedly communicated directly and specifically to minimize competition, including by substantially raising prices on dozens of topical products," she adds. Other generic manufacturers - Actavis, Mylan (MYL), Teva (TEVA), G&W, and Glenmark - did the same, according to the suit. "This massive antitrust conspiracy adversely impacted virtually every federal, state, and commercial payor, and every person in the United States who used or paid for a generic topical drug from 2009 through 2016," James contends. Reference Link

ShowHide Related Items >><<
TEVA Teva
$12.32 /

-0.36 (-2.84%)

TARO Taro Pharmaceutical
$66.78 /

-1.24 (-1.82%)

PRGO Perrigo
$55.26 /

-0.705 (-1.26%)

NVS Novartis
$88.16 /

-0.29 (-0.33%)

MYL Mylan
$17.84 /

-0.61 (-3.31%)

TARO Taro Pharmaceutical
$66.78 /

-1.24 (-1.82%)

02/04/20 H.C. Wainwright
Taro Pharmaceutical price target lowered to $94 from $110 at H.C. Wainwright
08/12/19 H.C. Wainwright
Taro Pharmaceutical price target lowered to $105 from $115 at H.C. Wainwright
TEVA Teva
$12.32 /

-0.36 (-2.84%)

06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
06/01/20
Fly Intel: Top five analyst upgrades
06/01/20 SunTrust
Teva upgraded to Buy from Hold at SunTrust
06/01/20 SunTrust
Teva upgraded to Buy from Hold at SunTrust
MYL Mylan
$17.84 /

-0.61 (-3.31%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
PRGO Perrigo
$55.26 /

-0.705 (-1.26%)

06/08/20 SVB Leerink
Perrigo price target raised to $63 from $55 at SVB Leerink
04/17/20
Argus cuts Perrigo to Hold on rising credit risk, generic price-fixing lawsuit
04/17/20 Argus
Perrigo downgraded to Hold from Buy at Argus
03/24/20 JPMorgan
JPMorgan upgrades 'highly defensive' Perrigo to Overweight from Neutral
NVS Novartis
$88.16 /

-0.29 (-0.33%)

06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
05/18/20 Jefferies
Jefferies names Beazley, Ferguson, Novartis, Rio Tinto high conviction ideas
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
TEVA Teva
$12.32 /

-0.36 (-2.84%)

PRGO Perrigo
$55.26 /

-0.705 (-1.26%)

NVS Novartis
$88.16 /

-0.29 (-0.33%)

MYL Mylan
$17.84 /

-0.61 (-3.31%)

TEVA Teva
$12.32 /

-0.36 (-2.84%)

PRGO Perrigo
$55.26 /

-0.705 (-1.26%)

MYL Mylan
$17.84 /

-0.61 (-3.31%)

TEVA Teva
$12.32 /

-0.36 (-2.84%)

PRGO Perrigo
$55.26 /

-0.705 (-1.26%)

NVS Novartis
$88.16 /

-0.29 (-0.33%)

MYL Mylan
$17.84 /

-0.61 (-3.31%)

TEVA Teva
$12.32 /

-0.36 (-2.84%)

PRGO Perrigo
$55.26 /

-0.705 (-1.26%)

NVS Novartis
$88.16 /

-0.29 (-0.33%)

MYL Mylan
$17.84 /

-0.61 (-3.31%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.